Monocyte Chemotactic Protein-1, Fractalkine, and Receptor for Advanced Glycation End Products in Different Pathological Types of Lupus Nephritis and Their Value in Different Treatment Prognoses.

Item request has been placed! ×
Item request cannot be made. ×
  Processing Request
  • Additional Information
    • Publication Year:
      2016
    • Author-Supplied Keywords:
      Anatomy
      Autoimmune diseases
      Biochemistry
      Biology and life sciences
      Biomarkers
      Biopsy
      Body fluids
      Clinical immunology
      Clinical medicine
      Creatinine
      Diagnostic medicine
      Immune response
      Immunology
      Inflammation
      Lupus nephritis
      Medicine and health sciences
      Pathology and laboratory medicine
      Physiology
      Prognosis
      Research Article
      Signs and symptoms
      Surgical and invasive medical procedures
      Urine
    • Abstract:
      Background: Early diagnosis is important for the outcome of lupus nephritis (LN). However, the pathological type of lupus nephritis closely related to the clinical manifestations; therefore, the treatment of lupus nephritis depends on the different pathological types. Objective: To assess the level of monocyte chemotactic protein (MCP-1), fractalkine (Fkn), and receptor for advanced glycation end product (RAGE) in different pathological types of lupus nephritis and to explore the value of these biomarkers for predicting the prognosis of lupus nephritis. Methods: Patients included in this study were assessed using renal biopsy. Class III and class IV were defined as the proliferative group, class V as non-proliferative group, and class V+III and class V+IV as the mixed group. During the follow-up, 40 of 178 enrolled patients had a poor response to the standard immunosuppressant therapy. The level of markers in the different response groups was tested. Results: The levels of urine and serum MCP-1, urine and serum fractalkine, and serum RAGE were higher in the proliferative group, and lower in the non-proliferative group, and this difference was significant. The levels of urine and serum MCP-1 and serum RAGE were lower in the poor response group, and these differences were also significant. The relationship between urine MCP-1 and urine and serum fractalkine with the systemic lupus erythematosus disease activity index was evaluated. Conclusion: The concentration of cytokines MCP-1, fractalkine, and RAGE may be correlated with different pathology type of lupus nephtitis. Urine and serum MCP-1 and serum RAGE may help in predicting the prognosis prior to standard immunosuppressant therapy. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of PLoS ONE is the property of Public Library of Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
    • ISSN:
      19326203
    • Accession Number:
      117015407
  • Citations
    • ABNT:
      LAN, L. et al. Monocyte Chemotactic Protein-1, Fractalkine, and Receptor for Advanced Glycation End Products in Different Pathological Types of Lupus Nephritis and Their Value in Different Treatment Prognoses. PLoS ONE, [s. l.], v. 11, n. 7, p. 1, 2016. Disponível em: . Acesso em: 15 out. 2019.
    • AMA:
      Lan L, Han F, Lang X, Chen J. Monocyte Chemotactic Protein-1, Fractalkine, and Receptor for Advanced Glycation End Products in Different Pathological Types of Lupus Nephritis and Their Value in Different Treatment Prognoses. PLoS ONE. 2016;11(7):1. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=117015407. Accessed October 15, 2019.
    • APA:
      Lan, L., Han, F., Lang, X., & Chen, J. (2016). Monocyte Chemotactic Protein-1, Fractalkine, and Receptor for Advanced Glycation End Products in Different Pathological Types of Lupus Nephritis and Their Value in Different Treatment Prognoses. PLoS ONE, 11(7), 1. Retrieved from http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=117015407
    • Chicago/Turabian: Author-Date:
      Lan, Lan, Fei Han, Xiabing Lang, and Jianghua Chen. 2016. “Monocyte Chemotactic Protein-1, Fractalkine, and Receptor for Advanced Glycation End Products in Different Pathological Types of Lupus Nephritis and Their Value in Different Treatment Prognoses.” PLoS ONE 11 (7): 1. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=117015407.
    • Harvard:
      Lan, L. et al. (2016) ‘Monocyte Chemotactic Protein-1, Fractalkine, and Receptor for Advanced Glycation End Products in Different Pathological Types of Lupus Nephritis and Their Value in Different Treatment Prognoses’, PLoS ONE, 11(7), p. 1. Available at: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=117015407 (Accessed: 15 October 2019).
    • Harvard: Australian:
      Lan, L, Han, F, Lang, X & Chen, J 2016, ‘Monocyte Chemotactic Protein-1, Fractalkine, and Receptor for Advanced Glycation End Products in Different Pathological Types of Lupus Nephritis and Their Value in Different Treatment Prognoses’, PLoS ONE, vol. 11, no. 7, p. 1, viewed 15 October 2019, .
    • MLA:
      Lan, Lan, et al. “Monocyte Chemotactic Protein-1, Fractalkine, and Receptor for Advanced Glycation End Products in Different Pathological Types of Lupus Nephritis and Their Value in Different Treatment Prognoses.” PLoS ONE, vol. 11, no. 7, July 2016, p. 1. EBSCOhost, search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=117015407.
    • Chicago/Turabian: Humanities:
      Lan, Lan, Fei Han, Xiabing Lang, and Jianghua Chen. “Monocyte Chemotactic Protein-1, Fractalkine, and Receptor for Advanced Glycation End Products in Different Pathological Types of Lupus Nephritis and Their Value in Different Treatment Prognoses.” PLoS ONE 11, no. 7 (July 26, 2016): 1. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=117015407.
    • Vancouver/ICMJE:
      Lan L, Han F, Lang X, Chen J. Monocyte Chemotactic Protein-1, Fractalkine, and Receptor for Advanced Glycation End Products in Different Pathological Types of Lupus Nephritis and Their Value in Different Treatment Prognoses. PLoS ONE [Internet]. 2016 Jul 26 [cited 2019 Oct 15];11(7):1. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=117015407